Assenagon Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Assenagon Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$101M	Sell	1,762,086 -158,572	-8%	-$8.69M	0.13%	138
2026 Q1	$108M	Buy	1,920,658 +501,591	+35%	+$29.2M	0.16%	102
2025 Q4	$84.3M	Buy	1,419,067 +1,074,929	+312%	+$58.5M	0.12%	142
2025 Q3	$18.6M	Sell	344,138 -695,346	-67%	-$39.8M	0.03%	380
2025 Q2	$57.1M	Buy	1,039,484 +230,362	+28%	+$13.6M	0.08%	193
2025 Q1	$57.2M	Buy	809,122 +197,455	+32%	+$13.3M	0.1%	188
2024 Q4	$40.2M	Buy	611,667 +502,695	+461%	+$33.7M	0.06%	237
2024 Q3	$7.66M	Sell	108,972 -243,502	-69%	-$20.4M	0.01%	593
2024 Q2	$29M	Buy	352,474 +349,329	+11,107%	+$29.1M	0.06%	222
2024 Q1	$275K	Sell	3,145 -13,842	-81%	-$1.24M	﹤0.01%	1303
2023 Q4	$1.64M	Sell	16,987 -86,091	-84%	-$7.62M	﹤0.01%	990
2023 Q3	$9.12M	Sell	103,078 -186,122	-64%	-$16.6M	0.03%	405
2023 Q2	$25.1M	Sell	289,200 -79,548	-22%	-$7.49M	0.09%	189
2023 Q1	$35.9M	Sell	368,748 -336,000	-48%	-$34.8M	0.13%	148
2022 Q4	$72.9M	Buy	704,748 +313,566	+80%	+$29.4M	0.26%	85
2022 Q3	$33.2M	Buy	391,182 +151,946	+64%	+$13.5M	0.13%	155
2022 Q2	$19.8M	Buy	239,236 +188,671	+373%	+$15M	0.07%	235
2022 Q1	$3.9M	Sell	50,565 -68,115	-57%	-$5.7M	0.01%	598
2021 Q4	$10.5M	Buy	118,680 +104,127	+716%	+$8.59M	0.03%	324
2021 Q3	$1.13M	Buy	+14,553	New	+$1.15M	﹤0.01%	870
2020 Q4	–	Sell	-7,111	Closed	-$541K	–	1031
2020 Q3	$541K	Sell	7,111 -13,865	-66%	-$1.4M	﹤0.01%	958
2020 Q2	$2.59M	Buy	20,976 +6,787	+48%	+$675K	0.02%	521
2020 Q1	$1.2M	Buy	+14,189	New	+$1.22M	0.01%	481
2018 Q2	–	Sell	-3,690	Closed	-$299K	–	457
2018 Q1	$299K	Sell	3,690 -696	-16%	-$59.7K	﹤0.01%	509
2017 Q4	$391K	Buy	+4,386	New	+$381K	﹤0.01%	631
2017 Q2	–	Sell	-3,680	Closed	-$323K	–	239
2017 Q1	$323K	Buy	+3,680	New	+$327K	0.01%	234

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Assenagon Asset Management's BMRN Position: Q2 2026 in Review

Assenagon Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.3% in Q2 2026, selling an estimated $8.69M and leaving 1,762,086 shares worth $101M. The position accounts for 0.13% of the portfolio, ranked #138.

Assenagon Asset Management first reported a position in BMRN in Q1 2017 and has held it in 26 quarters since. The position peaked at $108M in Q1 2026. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Assenagon Asset Management held 1,762,086 shares of BioMarin Pharmaceuticals worth $101M as of Q2 2026.
Assenagon Asset Management sold 158,572 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $8.69M.
BioMarin Pharmaceuticals made up 0.13% of Assenagon Asset Management's portfolio in Q2 2026, its #138 holding.
Assenagon Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 26 quarters since.
Assenagon Asset Management's BioMarin Pharmaceuticals position peaked at $108M in Q1 2026.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.